News & Updates
Showing Respirology articles
Showing

Is nintedanib safe, effective in patients with early-stage IPF?
Results of nintedanib use in patients with early-stage idiopathic pulmonary fibrosis (IPF) show a stable change in forced vital capacity (FVC) and a gradual decline in diffusing capacity of the lungs for carbon monoxide (DLCO) at week 52, according to an ongoing study presented at APSR 2023. In addition, treatment discontinuation is comparable to that in previous clinical trials.

Dupilumab, ruxolitinib deliver benefits to atopic dermatitis patients
Treatment with dupilumab increases the levels of bone alkaline phosphatase (BALP), a marker of bone mineralization, in paediatric patients with moderate-to-severe atopic dermatitis (AD), regardless of asthma comorbidity, reports a study presented at ACAAI 2023.

Biologic therapy improves life quality of asthmatic children
Treatment with biologic agents results in significant improvements in both function and quality of life among paediatric patients with moderate-to-severe asthma, according to a recent study presented at ACAAI 2023.

Physical activity aids in recovery of cardiopulmonary function after lung cancer surgery
Cardiopulmonary function (CPF) recovery failure at 6 months after lung cancer surgery appears to be driven by reductions in lung function and moderate-to-vigorous physical activity (MVPA) from baseline to 2 weeks, suggests a study. Baseline PA and dyspnoea are also associated with the inability to recover CPF.




